Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
A NEW treatment for multiple sclerosis has been made available for thousands of Scottish *sufferers for the first time.
Alemtuzumab, also known as Lemtrada, can be used to treat NHS patients after it was ruled to be good value for money, despite a £56,000 price tag.
An estimated 9,500 people in Scotland who have the more common relapsing remitting form of MS will become eligible to access the drug following the decision by the Scottish Medicines Consortium (SMC).
Scotland has the highest prevalence of MS in the world, with more than 11,000 people living with the condition.
Originally developed as a cancer treatment, alemtuzumab has been shown to reduce the frequency and severity of relapses, during which patients experience episodes of worsening neurological symptoms over a sustained period. The episodes can last weeks or months, may require hospital treatment and leave lingering health problems.
http://www.heraldscotland.com/news/...as-new-treatment-is-approved-for-nhs.24697725
Alemtuzumab, also known as Lemtrada, can be used to treat NHS patients after it was ruled to be good value for money, despite a £56,000 price tag.
An estimated 9,500 people in Scotland who have the more common relapsing remitting form of MS will become eligible to access the drug following the decision by the Scottish Medicines Consortium (SMC).
Scotland has the highest prevalence of MS in the world, with more than 11,000 people living with the condition.
Originally developed as a cancer treatment, alemtuzumab has been shown to reduce the frequency and severity of relapses, during which patients experience episodes of worsening neurological symptoms over a sustained period. The episodes can last weeks or months, may require hospital treatment and leave lingering health problems.
http://www.heraldscotland.com/news/...as-new-treatment-is-approved-for-nhs.24697725